GSK plc (NYSE:GSK) Shares Acquired by Hills Bank & Trust Co

Hills Bank & Trust Co raised its holdings in GSK plc (NYSE:GSK) by 7.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,284 shares of the pharmaceutical company’s stock after buying an additional 1,429 shares during the quarter. Hills Bank & Trust Co’s holdings in GSK were worth $789,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. KCS Wealth Advisory raised its holdings in shares of GSK by 1.5% in the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock worth $775,000 after purchasing an additional 314 shares during the period. Caprock Group LLC increased its position in shares of GSK by 2.8% in the fourth quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company’s stock worth $430,000 after acquiring an additional 317 shares in the last quarter. Horizon Bancorp Inc. IN raised its stake in shares of GSK by 8.9% in the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after acquiring an additional 323 shares during the period. MONECO Advisors LLC lifted its holdings in shares of GSK by 2.9% during the 4th quarter. MONECO Advisors LLC now owns 12,433 shares of the pharmaceutical company’s stock valued at $461,000 after acquiring an additional 346 shares in the last quarter. Finally, AdvisorNet Financial Inc boosted its position in GSK by 1.9% during the 4th quarter. AdvisorNet Financial Inc now owns 20,729 shares of the pharmaceutical company’s stock worth $768,000 after purchasing an additional 377 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GSK shares. Morgan Stanley initiated coverage on GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Finally, Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

GSK Stock Up 1.2 %

GSK stock traded up $0.53 during midday trading on Thursday, hitting $44.67. 4,924,269 shares of the company’s stock were exchanged, compared to its average volume of 3,466,009. The stock has a market capitalization of $92.58 billion, a price-to-earnings ratio of 16.18, a price-to-earnings-growth ratio of 1.85 and a beta of 0.65. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. The firm has a 50 day moving average price of $41.97 and a 200-day moving average price of $39.33. GSK plc has a 12-month low of $33.33 and a 12-month high of $44.72.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a dividend of $0.3762 per share. This represents a $1.50 dividend on an annualized basis and a yield of 3.37%. This is an increase from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio is 53.26%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.